Trials / Completed
CompletedNCT06706466
Evaluate the Prognostic Significance of Changes in the Systemic Immune-Inflammation Index in Patients with AGC Treated with ICI Therapy.
Systemic Immune-Inflammation Index As a Predictor of Neoadjuvant Treatment Efficacy in Advanced Gastric Cancer Based on a Dynamic Clinical Model
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 410 (actual)
- Sponsor
- Chang-Ming Huang, Prof. · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
The SIIR during neoadjuvant therapy can serve as a specific biomarker for predicting the efficacy of immunotherapy in patients with advanced gastric cancer.
Detailed description
A total of 410 patients with advanced gastric cancer treated with neoadjuvant chemotherapy (NAC group, 178) or immunotherapy (ICIs group, 232) were enrolled in two tertiary referral centers. The SIIR (\[SIIpost-treatment - SIIpre-treatment\] / SIIpre-treatment) was calculated. The diagnostic threshold for SIIR was set at the median value (-0.3) A joint model based on longitudinal trajectory and time-to-event analysis was used to assess the correlation between SIIR and the risk of death in patients with advanced gastric cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | observational study | Non-interventional |
Timeline
- Start date
- 2018-01-01
- Primary completion
- 2021-12-31
- Completion
- 2024-05-01
- First posted
- 2024-11-26
- Last updated
- 2024-11-26
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06706466. Inclusion in this directory is not an endorsement.